SARCLISA SC DIN 02571498
Status: Approved
Holder: SANOFI-AVENTIS CANADA INC
Health Canada record
| Active ingredient(s) | ISATUXIMAB 1400 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FC02 ISATUXIMAB |
|---|
| Original market date | |
|---|
| Current status date | 15-Sep-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ISATUXIMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02498235 | SARCLISA | SANOFI-AVENTIS CANADA INC | Solution | ISATUXIMAB 100 MG | Marketed |
| 02498243 | SARCLISA | SANOFI-AVENTIS CANADA INC | Solution | ISATUXIMAB 500 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 38284 | 2026-09-15 | Supplement to a New Drug Submission (SNDS) | New strength and route of administration |
Request a quote for SARCLISA SC
How to read a Canadian DIN record